CrushSCI.com
提供学术论文选刊润色服务
LEUKEMIA & LYMPHOMA 期刊封面 医学
返回期刊列表

Review Cycle Records

LEUKEMIA & LYMPHOMA

Taylor & Francis SCIE 非OA
2026新锐 4区2025中科院 4区2025 JCR Q3
71.1平均天数
69中位天数
2最短天数
152最长天数
3492025发文量

Paper Review Records

全部论文审稿周期

15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

4 天

Informing the debate: hypomethylating agents/venetoclax or intensive chemotherapy to treat acute myeloid leukemias

作者Michael Daunov; Yogen Saunthararajah

作者单位1. Department of Hematology and Oncology, University Hospitals; 2. School of Medicine, Case Western Reserve University; 3. Taussig Cancer Institute, Cleveland Clinic

PDF源文件 DOI 网页
61 天

Philadelphia-negative B-cell acute lymphoblastic leukemia developing after treatment for multiple myeloma: a case report

作者Chen Glait Santar; Ben-Zion Katz

作者单位1. The Cellular Immunophenotyping Unit, Hematology Institute, Tel Aviv Sourasky Medical Center

PDF源文件 DOI 网页
2 天

The role of radiotherapy in bridging to CAR T-cell therapy for high-grade B-cell lymphoma

作者Michael MacManus; Mark Dowling

作者单位1. Peter MacCallum Cancer Centre; 2. The Sir Peter McCallum Department of Oncology, University of Melbourne; 3. Royal Melbourne Hospital

PDF源文件 DOI 网页
143 天

The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review

作者Maïfa Belghoul; Andrea Kuhnl; Timothy Chevassut; Robin Sanderson; George Mikhaeel; Reuben Benjamin; Piers Patton; John Jones

作者单位1. Department of Clinical Experimental Medicine, Brighton and Sussex Medical School; 2. University Hospitals Sussex NHS Trust; 3. King’s College Hospital

PDF源文件 DOI 网页
152 天

Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison

作者Joshua Richter; Hans C. Lee; Sundar Jagannath; Jeffrey A. Zonder; James E. Hoffman; Zheng-Yi Zhou; Viviana Garcia-Horton; Mirko Fillbrunn; Hongjue Wang; Matthew Mattera; Timothy J. Inocencio; Yingxin Xu; James Harnett; Tito Roccia; Glenn S. Kroog; Karen Rodriguez Lorenc; Kate Knorr; Qiufei Ma; Naresh Bumma

作者单位1. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai; 2. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center; 3. Karmanos Cancer Institute, Wayne State University School of Medicine; 4. University of Miami Health System; 5. Analysis Group, Inc.; 6. Regeneron Pharmaceuticals, Inc.; 7. The Ohio State University Comprehensive Cancer Center

PDF源文件 DOI 网页
89 天

Extending the prognostic value of red cell distribution width to nodal T follicular helper cell lymphoma

作者Mitsuaki Oura; Daisuke Ikeda; Atsushi Uehara; Rikako Tabata; Kentaro Narita; Masami Takeuchi; Kosei Matsue

作者单位1. Division of Hematology/Oncology, Kameda Medical Center

PDF源文件 DOI 网页
67 天

Glofitamab for the treatment of relapsed/refractory hairy cell leukemia: a case report

作者Linwei Tan; Xingtong Wang; Yangzhi Zhao; Jia Li; Junna Li; Ou Bai; Wei Guo

作者单位1. Department of Hematology, The First Hospital of Jilin University

PDF源文件 DOI 网页
70 天

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial

作者Priyanka Mehta; Roderick Murphy; Saemi Park; Stefan Faderl; Tomas Skacel; Abin Thomas; Sean Johnson; Alex Legg

作者单位1. University Hospitals Bristol and Weston NHS Foundation Trust; 2. Jazz Pharmaceuticals plc; 3. Centre for Trials Research, Cardiff University

PDF源文件 DOI 网页
69 天

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison

作者Oren Pasvolsky; Curtis Marcoux; Denái R. Milton; Mark R. Tanner; Qaiser Bashir; Samer Srour; Neeraj Saini; Paul Lin; Jeremy Ramdial; Yago Nieto; Guilin Tang; Yosra Aljawai; Asad A. Haider; Bilal Islam; Hans C. Lee; Krina K. Patel; Mahmoud R. Gaballa; Partow Kebriaei; Sheeba K. Thomas; Robert Z. Orlowski; Richard E. Champlin; Elizabeth J. Shpall; Muzaffar H. Qazilbash

作者单位1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center; 2. Division of Hematology, Dalhousie University; 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center; 4. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center; 5. Department of Hematopathology, The University of Texas MD Anderson Cancer Center; 6. Department of Medicine, Dow University of Health Sciences; 7. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center

PDF源文件 DOI 网页
72 天

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study

作者Annasofia Holopainen; Hanna-Riikka Lehto; Taru Kuittinen; Mikko Nuutinen; Kristiina Tyynelä-Korhonen; Annamarja Lamminmäki; Tiina Saarto; Timo Carpén

作者单位1. Department of Hematology, Kuopio University Hospital, The Wellbeing Services County of North Savo; 2. Faculty of Health Sciences, Institute of Clinical Medicine, University of Eastern Finland; 3. Department of General Medicine, Division of Palliative Medicine, University of Turku; 4. Palliative Care Centre and Hospital at Home, The Wellbeing Services County of Western Uusimaa; 5. Nordic Healthcare Group; 6. Palliative Care Center, Päijät-Häme Wellbeing Services County; 7. Cancer Center, Kuopio University Hospital, The Wellbeing Services County of North Savo; 8. Palliative Care Center, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki

PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿96.4 天

中位数77 天

Contact CrushSCI

联系 CrushSCI

扫码添加微信,或留下手机号/微信号,我们将与你确认稿件阶段、编辑需求和投稿计划。

当前选择:论文编辑服务

也可以预留联系方式

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。